PFMT Postpartum: 2 Critical Approaches Compared
Antenatal versus postnatal initiation of pelvic floor muscle training, and the durability of effect across major randomised trials and the 2020 Cochrane synthesis.
One-Minute Takeaway on PFMT Postpartum
What the evidence shows at a glance:
- PFMT postpartum prevention is most effective when initiated antenatally in continent nulliparas, with the largest Cochrane subgroup analysis showing roughly a 62% relative reduction in urinary incontinence in late pregnancy.
- Effects on postpartum incontinence in the early postnatal period (3–6 months) are smaller and less consistent, with relative reductions of around 29% when antenatal training is the index intervention.
- Postnatal-only PFMT in unselected women shows minimal benefit for primary prevention, though it remains effective as treatment for women already symptomatic.
- Durability beyond 12 months is uncertain — the largest long-term follow-up (Glazener 12 years) showed effects attenuate substantially once supervised training ends.
Why This Topic Matters
Urinary incontinence is one of the most common, and most under-reported, complications of pregnancy and childbirth. Around one in three women experiences urinary leakage in the third trimester, and roughly a quarter remain symptomatic at three months postpartum.
For many clinicians, the question is not whether pelvic floor muscle training works, but when to start it and who benefits most. Antenatal initiation, postnatal initiation, and selective treatment of symptomatic women carry different evidence bases and different practical demands on the patient.
The 2020 Cochrane review by Woodley and colleagues consolidated 46 trials in over 10,000 women, providing the most rigorous synthesis to date. PFMT postpartum strategies that combine antenatal initiation with adequate supervision now have the strongest evidence base for primary prevention.
Yet meaningful uncertainty persists about durability, optimal dose, and whether benefits seen in trial settings translate to routine antenatal care. This review synthesises the trial evidence by theme rather than by individual study, with the goal of answering the practical question every obstetric clinician faces in clinic.
Evidence Reviewed
This synthesis is anchored on the updated Cochrane systematic review and meta-analysis (Woodley 2020), and triangulated against the prior 2012 Cochrane version, the Dumoulin 2018 Cochrane review on PFMT for established urinary incontinence, and several major randomised trials of antenatal and postnatal initiation. Together, they form a body of moderate- to high-certainty evidence on the question of timing.
The evidence base for PFMT postpartum prevention spans roughly two decades, with a clear shift over time toward supervised, structured antenatal programmes. The table below compares the key studies that inform current recommendations.
| Study / Source | Design | Population | n | Timing | Key Effect Estimate |
|---|---|---|---|---|---|
| Woodley 2020 (Cochrane) | SR/MA | Antenatal & postnatal women | ~10,832 | Both | RR 0.38 (95% CI 0.20–0.72) late preg UI, continent subgroup |
| Boyle 2012 (Cochrane) | SR/MA | Antenatal & postnatal women | ~8,485 | Both | RR 0.71 (95% CI 0.54–0.95) for UI >3 mo postpartum |
| Mørkved 2003 | RCT, single-blind | Continent nulliparas | 301 | Antenatal | 32% vs 48% UI at 36 wks; RR 0.65 (p<0.01) |
| Stafne 2012 | RCT | Healthy nulliparas, mixed | 855 | Antenatal | 11% vs 19% UI at 36 wks; OR 0.52 |
| Hilde 2013 | RCT | Postpartum continent primiparas | 175 | Postnatal | No significant effect on UI at 6 mo (NS) |
| Sigurdardottir 2020 | Assessor-blind RCT | Symptomatic primiparas | 84 | Postnatal | Significant reduction in UI symptom severity at 12 mo |
| Pelaez 2014 | RCT | Continent nulliparas, exercise+PFMT | 169 | Antenatal | 3.5% vs 19.2% UI late pregnancy; OR 0.16 |
| Glazener 2014 | RCT, 12-yr follow-up | Symptomatic postpartum | 516 | Postnatal | No significant difference at 12 yrs; early effect attenuated |
| Reilly 2002 | RCT | Nulliparas, high bladder neck mobility | 268 | Antenatal | 19.2% vs 32.7% UI at 3 mo postpartum; RR 0.59 |
| Dumoulin 2018 (Cochrane) | SR/MA | Women with established UI | ~3,000 | Treatment | Strong evidence for PFMT as first-line UI treatment |
Key Findings on PFMT Postpartum by Theme
Synthesising across trials, four themes emerge: antenatal initiation in continent women carries the strongest prevention signal; postnatal-only initiation in unselected women is largely ineffective for primary prevention; benefits attenuate without continued practice; and supervision dose matters more than total exercise volume.
Antenatal initiation: the strongest prevention signal
Across multiple trials, antenatal PFMT initiated in continent nulliparas produces the largest and most consistent prevention effect. The Cochrane 2020 subgroup analysis of continent women found a relative risk of 0.38 (95% CI 0.20–0.72) for late-pregnancy urinary incontinence, equivalent to roughly a 62% relative reduction.
This subgroup finding is supported by individual trials including Mørkved 2003, Pelaez 2014, and Reilly 2002. Each enrolled continent or near-continent women in mid-pregnancy and delivered supervised programmes of 8–12 weeks. PFMT postpartum benefit in this cohort extends into the early postnatal period, with relative reductions around 29% at 3–6 months.
The Stafne 2012 trial extended this signal to a healthy mixed-continence population, finding an absolute reduction in late-pregnancy UI from 19% to 11%. Effect sizes were smaller than in pure continent cohorts, but consistent in direction.
Postnatal-only initiation: limited primary prevention benefit
Trials initiating PFMT exclusively after delivery in unselected women show much weaker effects. The Hilde 2013 RCT of postpartum continent primiparas found no significant reduction in urinary incontinence at six months, despite a structured supervised programme.
This pattern likely reflects two factors. First, the antenatal period appears to be a sensitive window for neuromuscular adaptation before the mechanical insult of vaginal delivery. Second, many women who initiate PFMT only postnatally are already symptomatic, shifting the question from prevention to treatment.
Where PFMT postpartum is delivered to women already experiencing leakage, evidence is more favourable. The Sigurdardottir 2020 trial in symptomatic primiparas showed clinically meaningful reductions in symptom severity sustained at 12 months. This aligns with the Dumoulin 2018 Cochrane review, which provides strong evidence for PFMT as first-line treatment.
Durability of effect: the central uncertainty
The most pressing limitation of PFMT postpartum data is the question of durability. Short-term efficacy is well-established, but maintenance of benefit beyond the supervised intervention period is far less certain.
The Glazener 2014 12-year follow-up of an early postnatal PFMT trial provides the longest-term data available. By 12 years, the early intervention advantage had largely disappeared, with similar incontinence prevalence in both arms.
Bø & Hilde 2013 reached a similar conclusion in a systematic review of long-term outcomes, finding that adherence to home practice declines markedly within 12–24 months of supervised programme completion. The clinical implication is that PFMT postpartum benefit is contingent on continued practice.
Whether maintenance strategies — periodic booster sessions, digital reminders, app-based programmes — can preserve early gains is an open question with limited trial-level evidence to date.
Synthesis pearl: The prevention signal for PFMT postpartum is real and biologically plausible, but it is concentrated in continent women trained antenatally with adequate supervision. Effects in unselected postpartum populations and effects beyond 12 months are far less robust.
The continent antenatal cohort represents the most favourable trial setting for several reasons. The neuromuscular system has not yet been challenged by vaginal delivery, so training can build reserve before the insult. Motivation and adherence are typically higher in pregnancy than in the early postpartum period, when sleep deprivation and infant care compete for time.
Postnatal mixed cohorts, by contrast, include women whose pelvic floors have already been damaged by delivery, women who are already symptomatic, and women with substantial competing demands. The same intervention applied to these heterogeneous groups produces a smaller average effect.
Across trials, the strongest predictor of effect size is not total session volume but the proportion of sessions that are supervised by a trained physiotherapist or nurse. Self-directed home programmes show smaller and more variable benefits than supervised group or individual programmes.
The Mørkved 2003 protocol, often cited as a reference standard for PFMT postpartum trials, delivered weekly supervised group sessions for 12 weeks, with daily home practice. Adaptations that reduce supervision intensity tend to dilute the effect.
The 2020 Cochrane review separates trials by population (continent vs symptomatic, mixed vs primary prevention) and by timing (antenatal vs postnatal). Heterogeneity is substantial across the full dataset but shrinks within carefully defined subgroups.
This means a single pooled estimate across all 46 trials can be misleading. The clinically actionable estimates come from subgroup analyses, particularly the continent antenatal subgroup, which most closely matches the primary prevention question many clinicians want to answer.
Mode of delivery, instrumental delivery, prolonged second stage, and large infant birthweight all increase baseline incontinence risk and may modify PFMT response. Several trials have observed that women with the highest baseline risk tend to derive the largest absolute benefit, even when relative effects are similar.
Reilly 2002 selectively enrolled nulliparas with increased bladder neck mobility on ultrasound and reported one of the largest absolute reductions in postpartum stress incontinence, suggesting risk stratification could enhance the cost-effectiveness of PFMT postpartum prevention strategies.
Quality and Consistency of PFMT Postpartum Evidence
The evidence base for PFMT postpartum prevention is mature but uneven. Methodological quality has improved substantially over the past two decades, with more recent trials using assessor blinding, validated outcome measures, and intention-to-treat analysis. Earlier trials often relied on self-reported leakage without standardised assessment.
Knowledge Gaps
Despite a large evidence base, several practical questions remain unanswered. These gaps are not merely academic — they shape how clinicians counsel patients and how health systems decide whether to fund antenatal PFMT programmes.
What the Evidence Does NOT Show
- Durability beyond 12 months in unselected populations — long-term follow-up is sparse and the available data suggest attenuation.
- Optimal dose for prevention — total session count, daily contraction prescription, and supervision intensity have not been directly compared in adequately powered head-to-head trials.
- Effectiveness in routine antenatal care — trial protocols often deliver more supervision than real-world clinics provide; generalisability to standard practice is uncertain.
- Comparative effectiveness vs other modalities — biofeedback, vaginal cones, electrical stimulation, and digital app-based programmes have not been rigorously compared to standard supervised PFMT postpartum protocols.
- Subgroup response by obstetric risk factors — operative delivery, prolonged second stage, and large infant birthweight may modify response, but trials are underpowered for these analyses.
The most consequential gap is durability. If PFMT postpartum benefit is contingent on continued practice, then a brief antenatal programme may produce only short-term gains unless paired with maintenance strategies. Trials of digital adherence supports and booster sessions are emerging but not yet decisive.
Practical Implications for PFMT Postpartum Care
The evidence suggests several patterns clinicians can apply when counselling pregnant and postpartum women about pelvic floor training. These should be framed as evidence-supported considerations rather than prescriptive directives, since individual circumstances vary considerably.
Evidence Supports Antenatal Initiation in Continent Women
The strongest prevention signal applies to nulliparas who are continent at trial entry. Counselling about supervised antenatal PFMT in mid-pregnancy is reasonable based on consistent trial evidence.
Supervised Programmes Show Larger Effects
Trials with weekly supervised sessions produced larger effects than self-directed home programmes. When local services allow, referral to pelvic floor physiotherapy is supported by the evidence.
Symptomatic Women Benefit from Treatment PFMT Postpartum
For women already experiencing postpartum urinary incontinence, the Sigurdardottir trial and Dumoulin Cochrane review both support PFMT as effective first-line therapy with sustained benefit at 12 months.
Durability Counselling Reflects Honest Uncertainty
Patients should be informed that benefit appears largest in the short and medium term, and that continued practice is likely needed to maintain effect. The 12-year Glazener data should temper claims of permanent prevention.
Evidence Grade and Bottom Line
Overall Evidence Grade: Moderate. The evidence supporting antenatal PFMT for primary prevention in continent women is strong and consistent across multiple RCTs and the 2020 Cochrane synthesis. Evidence for postnatal-only initiation, long-term durability, and optimal dose is weaker, with greater heterogeneity and shorter follow-up.
Bottom Line
- Supervised pelvic floor muscle training initiated in mid-pregnancy in continent nulliparas substantially reduces urinary incontinence in late pregnancy and the early postpartum period.
- Postnatal-only initiation in unselected, asymptomatic women shows minimal benefit for primary prevention but remains effective as treatment for women who develop symptoms.
- The 2020 Cochrane synthesis provides the most rigorous summary of effect estimates, with strongest signals concentrated in the continent antenatal subgroup.
- Durability beyond 12 months is uncertain; available long-term data suggest the early intervention advantage attenuates without ongoing practice.
- Optimal dose, supervision intensity, and comparative effectiveness against other modalities remain unresolved and warrant further research.
Article Information
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Woodley SJ, Lawrenson P, Boyle R, Cody JD, Mørkved S, Kernohan A, Hay-Smith EJC. Pelvic floor muscle training for preventing and treating urinary and faecal incontinence in antenatal and postnatal women. Cochrane Database Syst Rev. 2020;5(5):CD007471. DOI: 10.1002/14651858.CD007471.pub4
- Boyle R, Hay-Smith EJC, Cody JD, Mørkved S. Pelvic floor muscle training for prevention and treatment of urinary and faecal incontinence in antenatal and postnatal women. Cochrane Database Syst Rev. 2012;10(10):CD007471. DOI: 10.1002/14651858.CD007471.pub2
- Mørkved S, Bø K, Schei B, Salvesen KÅ. Pelvic floor muscle training during pregnancy to prevent urinary incontinence: a single-blind randomized controlled trial. Obstet Gynecol. 2003;101(2):313-19. DOI: 10.1016/s0029-7844(02)02711-4
- Glazener CMA, MacArthur C, Hagen S, Elders A, Lancashire R, Herbison GP, Wilson PD. Twelve-year follow-up of conservative management of postnatal urinary and faecal incontinence and prolapse outcomes: randomised controlled trial. BJOG. 2014;121(1):112-20. DOI: 10.1111/1471-0528.12473
- Stafne SN, Salvesen KÅ, Romundstad PR, Torjusen IH, Mørkved S. Does regular exercise including pelvic floor muscle training prevent urinary and anal incontinence during pregnancy? A randomised controlled trial. BJOG. 2012;119(10):1270-80. DOI: 10.1111/j.1471-0528.2012.03426.x
- Hilde G, Stær-Jensen J, Siafarikas F, Ellström Engh M, Bø K. Postpartum pelvic floor muscle training and urinary incontinence: a randomized controlled trial. Obstet Gynecol. 2013;122(6):1231-38. DOI: 10.1097/AOG.0000000000000012
- Sigurdardottir T, Steingrimsdottir T, Geirsson RT, Halldorsson TI, Aspelund T, Bø K. Can postpartum pelvic floor muscle training reduce urinary and anal incontinence type symptoms in primiparous women? A randomized controlled trial. Am J Obstet Gynecol. 2020;222(3):247.e1-247.e8. DOI: 10.1016/j.ajog.2019.09.011
- Pelaez M, Gonzalez-Cerron S, Montejo R, Barakat R. Pelvic floor muscle training included in a pregnancy exercise program is effective in primary prevention of urinary incontinence: a randomized controlled trial. Neurourol Urodyn. 2014;33(1):67-71. DOI: 10.1002/nau.22381
- Dumoulin C, Cacciari LP, Hay-Smith EJC. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev. 2018;10(10):CD005654. DOI: 10.1002/14651858.CD005654.pub4
- Reilly ETC, Freeman RM, Waterfield MR, Waterfield AE, Steggles P, Pedlar F. Prevention of postpartum stress incontinence in primigravidae with increased bladder neck mobility: a randomised controlled trial of antenatal pelvic floor exercises. BJOG. 2002;109(1):68-76. DOI: 10.1111/j.1471-0528.2002.t01-1-01116.x
- Bø K, Hilde G. Does it work in the long term? A systematic review on pelvic floor muscle training for female stress urinary incontinence. Neurourol Urodyn. 2013;32(3):215-23. DOI: 10.1002/nau.22292
- Sangsawang B, Sangsawang N. Stress urinary incontinence in pregnant women: a review of prevalence, pathophysiology, and treatment. Int Urogynecol J. 2013;24(6):901-12. DOI: 10.1007/s00192-013-2061-7